Posts by 141 Creative
The Amyloid Paradox: What Can Alzheimer’s Disease Drug Development Learn from Oncology?
By Dennis Chang This week, the FDA approved Biogen and Eisai’s anti-amyloid antibody aducanumab (Aduhelm) for Alzheimer’s disease (AD). The controversy embroiling this decision has been and will likely continue to be heated. However, regardless of whether or not one believes the FDA decision was the correct one, it is apparent that aducanumab is at…
Read MoreOncology R&D Outlook 2020: The Ongoing Impact of COVID-19
By Dennis Chang, Dan Holohan, Edouard Mullarky, and Rachit Neupane COVID-19 has escalated into a global pandemic with shocking speed and poses an unprecedented challenge for all facets of society. Oncology research and development has been no exception. Necessary measures to slow the spread of the disease (e.g. travel restrictions, quarantines, and social distancing), or…
Read More2019 Oncology Outlook
Oncology drug development continues at an unprecedented pace—our experts examine recent trends and detail what to expect this year: The first immunotherapy + targeted therapy combinations on the verge of launch Immune checkpoint inhibitors have received over 40 FDA approvals already, but thus far all approvals have been for IO monotherapy or for IO+IO or…
Read More2018 Oncology Year in Review: New Cancer Drug Approvals
In 2018, the biopharma industry made groundbreaking advances in oncology with 44 drug approvals in the US. “The pace of progress in cancer treatment is extraordinary and is the result of our industry and research community pushing forward on all fronts,” observes Dennis Chang, principal at Clarion. Below we highlight several of these approvals, encompassing…
Read More